Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Feb 1;12(2):311-318.
doi: 10.1093/scan/nsw124.

High reward expectancy during methylphenidate depresses the dopaminergic response to gain and loss

Affiliations
Randomized Controlled Trial

High reward expectancy during methylphenidate depresses the dopaminergic response to gain and loss

E A Evers et al. Soc Cogn Affect Neurosci. .

Abstract

Dopamine plays an important role in goal-directed behavior, through its modulatory influence on striatal neurons. It is unclear whether tonic dopamine levels, which regulate the vigor of acting, interact with the phasic dopamine response to reward that drives instrumental behavior. In a randomized placebo-controlled study in healthy volunteers, we show that methylphenidate, a drug that increases tonic dopamine levels, systematically reduced striatal phasic BOLD responses to gain and loss in a gambling task as measured with fMRI. It also increased response vigor and reward expectancy-related BOLD signals in the ventral striatum. These findings suggest that striatal tonic dopamine levels constitute an average reward expectation signal that modulates the phasic dopaminergic response to reward. This offers opportunities for treatment of behavioral disorders associated with abnormal reward sensitivity.

Keywords: Pharmacological fMRI; dopamine; feedback; gambling.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
During fMRI scanning participants performed a gambling task with the intent to win as many points as possible. A fixation cross was presented for 0.5 s followed by the numbers ‘5’ and ‘25’ (choice cue). The left/right position of these cues was randomized. Participants chose a number by pressing the corresponding button. One second later, the boxes around the numbers turned both green (indicating gain) and both red (indicating loss) and stayed on the screen for 1.5 s. The intertrial interval was 3 s plus RT. When participants chose ‘5’, they could gain or lose 5 (80% of trials, expected small gain or loss), 7 (10%, unexpected small gain or loss) or 125 points (10%, unexpected large gain or loss); when they chose ‘25’, they could win or lose 25 (80%, expected small gain or loss), 27 (10%, unexpected small gain or loss), or 125 points (10%, unexpected large gain or loss). In the present example, the participant chose ‘5’, and gained 125 points. The color bar below indicated the total amount of points collected so far.
Fig. 2.
Fig. 2.
The average reaction time (in ms) on the next trial for the different gain and loss events, during placebo and MPH (with SDs).
Fig. 3.
Fig. 3.
A shows the ventral striatal cluster for which the BOLD response is positively correlated with the RPE in the placebo condition (model 1), and B shows the ventral striatal cluster for which the BOLD response correlates positively with the RPE history during placebo (model 3). Both clusters are shown at coronal slices at x = 15.
Fig. 4.
Fig. 4.
The average percentage signal change (n = 20) with SEM across the two ventral striatal clusters (A) (coronal slices at x = 15) for Choice (B) and for the different types of feedback (C) during the placebo and MPH session (model 4).

Similar articles

Cited by

References

    1. Advokat C. (2010). What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD). Neuroscience and Biobehavioral Reviews, 34(8), 1256–66. - PubMed
    1. Antonelli F., Strafella A.P. (2014). Behavioral disorders in Parkinson’s disease: the role of dopamine. Parkinsonism and Related Disorders, 20(Suppl 1), S10–2. - PubMed
    1. Beaulieu J.M., Gainetdinov R.R. (2011). The physi ology, signaling, and pharmacology of dopamine receptors. Pharmacological Review, 63(1), 182–217. - PubMed
    1. Beierholm U., Guitart-Masip M., Economides M., et al. (2013). Dopamine modulates reward-related vigor. Neurop sychopharmacology, 38(8), 1495–503. - PMC - PubMed
    1. Bond A., Lader M. (1974). The use of analogue scales in rating subjective feelings. British Journal of Medical Psychology, 47, 211–8.

Publication types